Objective. To evaluate the longer-term efficacy of etanercept in patients with severe and advanced active AS. Conclusion. Despite the improvements in symptoms and inflammatory markers observed shortly after initiation of once-weekly etanercept, there was no notable plateauing effect on patient-reported outcomes. Indeed, signs and symptoms of severe and advanced active AS continued to improve after up to 24 weeks, treatment with etanercept.
Introduction
AS is a chronic inflammatory rheumatic disease that predominantly affects the axial skeleton, causing inflammatory back pain, with progression towards irreversible ankylosis and thoracic kyphosis [1, 2] . In advanced stages of the disease, vertebral fusion typically ascends the spine, leading to the formation of a long bony column described as bamboo spine [1] . This results in significant functional disability, as well as loss of productivity and employment [35] .
TNF blockers, which have been shown to improve clinical outcomes in patients with active inflammatory disease, have transformed the treatment of AS [610] . However, most studies investigating TNF blockers excluded patients with complete ankylosis of the spine [69] . Three previous studies evaluated the efficacy of TNF blockers (infliximab and adalimumab) in patients with advanced, active AS, but these were either observational [11, 12] or retrospective [13] in nature, lacking a control group [12] or involving few patients [11, 13] . The SPINE study was the first randomized, placebo-controlled study undertaken specifically in patients with severe, advanced AS and investigating the efficacy of etanercept in this patient population [14] . This study demonstrated that etanercept was associated with significant improvements in symptoms and disease severity (in terms of spinal mobility and pulmonary function) in patients with severe and advanced disease. However, while the 12-week double-blind treatment period in the SPINE study was able to demonstrate the onset of action and efficacy of etanercept in this patient population, it was unable to provide data on the sustainability of the response to etanercept.
Therefore a prospective, 12-week, open-label extension of the SPINE study was conducted to determine if patients with severe, advanced AS receiving longer-term etanercept therapy experienced further improvement in the signs and symptoms of AS during continued therapy with etanercept (or if a plateau effect would occur).
Methods

Study design
This was a 12-week open-label extension of a previous 12-week randomized, double-blind, placebo-controlled, multicentre study (clinical trial registration number NCT00420238) conducted in 21 centres in four European countries (France, Germany, the Netherlands and Hungary), which compared s.c. etanercept 50 mg once weekly with placebo [14] .
The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was consistent with the guidelines for good clinical practices International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-E6) and regulations. The study was approved by the ethics committees of the Comité de Protection des Personnes Ile de France III (France), the BfArm (Germany), National Institute of Pharmacy (Hungary) and Centrale Commissie Mensgebonden Onderzoek (CCMO) (the Netherlands) and written informed consent was obtained from each patient before the study.
Patients
Men and women aged 1870 years who had completed the initial double-blind study were eligible to participate in the open-label extension. Briefly, patients included in the double-blind study had a current diagnosis of advanced or severe AS according to modified New York criteria [15] . Advanced or severe AS was defined by the presence of at least one of the following three criteria: (i) two intervertebral adjacent bridges and/or fusion at the lumbar spine; (ii) three inter-vertebral adjacent bridges and/or fusion at the thoracic spine; and (iii) two inter-vertebral adjacent bridges and/or fusion at the cervical spine. Patients had active disease, defined as a BASDAI score of 540 despite receiving at least two NSAIDs at the maximum tolerated dose for >3 months. Patients also had to have baseline axial neck, back or hip pain defined as a score of 530 on a 0100 mm visual analogue scale (VAS). Patients were excluded from the double-blind study if they had a previous history of TNF blocker use, if they had a change in the dose of NSAIDs within 2 weeks of the baseline evaluation and if the dose of concomitant, conventional DMARD (e.g. SSZ, MTX) had changed within 4 weeks of baseline evaluation. 
Interventions
Outcome measures
Efficacy measures were assessed at baseline of the double-blind study (week 0) and weeks 2, 4, 12, 14, 18 and 24 and included the 0100 scale assessments of BASDAI [16] , BASFI [17] , BASMI 10 [18, 19] and total back pain (assessed using a VAS scale). CRP levels were also assessed, as was the ASDAS-CRP. The proportion of patients who achieved a 20 or 40% response according to the Assessment in AS (ASAS) International Working Group (ASAS 20 and ASAS 40), ASAS partial remission rate, ASAS 5/6 response rate and the proportion of patients who experienced a 50% improvement from baseline in BASDAI (BASDAI 50 response rate) were also assessed at each visit.
The safety of etanercept was also assessed at each study visit in all patients who received at least one dose of study medication. Safety assessments included adverse events, premature discontinuations and laboratory tests.
Statistical analyses
Descriptive statistical analyses were conducted in the evaluable population, with the last observation carried forward for missing values. The evaluable population was defined as all patients who entered the open-label extension. Efficacy and safety data are reported in this population. Efficacy data for the evaluable open-label population are presented from the beginning of the randomized, double-blind, placebo-controlled study (week 0; baseline). Changes in efficacy parameters are therefore presented over a 24-week period. Concerning safety data, only data collected from the beginning of the open-label extension are presented, as those from the randomized period have already been presented [14] .
Results
Patients
Of the 82 patients who were randomized in the double-blind study, 77 completed the 12 weeks of treatment (38 from the etanercept group and 39 from the placebo group) and entered the open-label extension ( Fig. 1) . The baseline (beginning of double-blind study) demographics and disease characteristics of patients who entered the open-label extension are presented in Table 1 . Briefly, patients were mostly male (92%) with a mean (S.D.) age of 47.5 (10.5) years and a mean disease duration of 16 (10.7) years. Patients had active, severe disease at baseline, with a mean (S.D.) BASDAI of 61.5 On pelvic X-ray assessment (e.g. BASRI hip score of at least two at either the right or left hip). mSASSS: modified Stoke ankylosing spondylitis spine score. 
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Continuous efficacy of etanercept (13.2), BASMI of 5.7 (1.4) and a modified Stoke ankylosing spondylitis spine score of 37 (20.2). Demographic and disease characteristics of the open-label patient population were similar to those of the overall patient population (n = 82) in the double-blind study (data not shown) [14] .
Efficacy
The mean change from baseline in BASDAI score for the etanercept/etanercept group was À27.4 (23.8) at the end of the double-blind study. The BASDAI score continued to decrease during the open-label extension, with a mean change from baseline of À37.6 (22.4) at 24 weeks ( Table 2 ). In comparison, the mean change from baseline in BASDAI score for the placebo/etanercept group was À15.0 (20.0) at the end of the double-blind study, with a mean change from baseline of À28.6 (24.3) at 24 weeks ( Table 2 ). The magnitude of effect of etanercept over 12 weeks on AS disease activity in patients who switched from placebo was generally similar to that observed in patients who received etanercept during the double-blind study (Fig. 2a) . BASFI and BASMI scores followed a similar trend. At weeks 12 and 24, the respective mean changes from baseline in BASFI scores were À22.4 (19.5) and À28.9 (20.8) in the etanercept/etanercept group and À10.7 (18.5) and À21.8 (20.9) in the placebo/ etanercept group (Table 2 ; Fig. 2b ). At weeks 12 and 24, the respective mean changes from baseline in BASMI scores were À0.6 (0.8) and À0.8 (0.8) in the etanercept/ etanercept group and À0.2 (0.6) and À0.5 (0.7) in the placebo/etanercept group (Table 2) .
Total back pain was also reduced with longer-term etanercept therapy (Table 2) , with a reduction from baseline in total back pain of À44.5 (25.1) in the etanercept/etanercept group. In patients who switched from placebo to treatment with etanercept during the open-label extension, total back pain decreased to similar levels achieved with etanercept treatment during the double-blind study, with a mean change from baseline in total back pain at week 24 of À32.3 (31.8) ( Table 2) .
CRP levels, which reached a plateau at week 2 of the double-blind study in the etanercept/etanercept group, generally remained stable during the open-label extension (Table 2 Fig. 2c ). Fig. 3 shows the proportion of patients who achieved BASDAI 50, ASAS 20, ASAS 40 and ASAS partial responses over the duration of the study. In the etanercept/etanercept group, the proportion of patients with a response in each of these parameters generally continued to increase from the beginning of the study, with no plateauing effect (Fig. 3) . At the end of the double-blind study, 18 (47.4%) patients receiving etanercept had achieved a BASDAI 50 response and after a further 12 weeks' treatment this had increased to 25 (65.8%) (Fig. 3a) . The additional seven patients who achieved BASDAI 50 only at week 24 had a median improvement from baseline in BASDAI score of 35.9% after 12 weeks. In comparison, among patients receiving placebo, the proportion of patients who achieved a BASDAI 50 response at week 12 was 25.6%. After being switched to etanercept therapy, the proportion of BASDAI 50 responders increased to 48.7% at week 24 (Fig. 3a) .
FIG. 2 Mean scores (S.E.M.) for (a) BASDAI (b) BASFI and (c) CRP levels in patients in
Similarly, at the end of the double-blind study, 68.4% of patients in the etanercept group and 35.9% of those in the placebo group had achieved an ASAS 20 response (Fig. 3b) . In the extension study, 84.2% of the etanercept/etanercept patients were ASAS 20 responders at week 24 (Fig. 3b) . After being switched to etanercept therapy, the proportion of ASAS 20 responders in the placebo/etanercept group initially increased markedly, then continued to increase, with up to two-thirds of patients achieving a response by week 24 (Fig. 3b) . ASAS 40 and ASAS partial remission followed a similar trend of continual improvement over 24 weeks in the etanercept/ etanercept group, while the improvement began from week 12 in the placebo/etanercept group ( Fig. 3c and d) .
The proportion of patients who achieved a clinically important improvement or a major improvement in ASDAS-CRP score (representing an improvement of 51.1 point or 52.0 points, respectively [20] ) is shown in Fig. 4 . More than three-quarters of patients who received etanercept for 24 weeks achieved a clinically important improvement and 50% demonstrated a major improvement (Fig. 4a) . A similar proportion of patients who switched from placebo to etanercept during the open-label extension achieved a clinically significant or major improvement as those who received etanercept during the double-blind study (Fig 4a) . The number of patients who achieved ASDAS-CRP inactive disease status (ASDAS-CRP score of <1.3) or ASAS 5/6 responder status is shown in Fig. 4b .
Safety
The safety results from the randomized controlled phase have previously been reported [14] . Here we present the safety results from the open-label extension (Table 3) . No unexpected adverse events or changes in laboratory values/vital signs were observed throughout the open-label extension. At least one treatment-emergent adverse event was reported in 42.1% of patients in the etanercept/etanercept group (n = 38) and in 56.4% of patients in the placebo/etanercept group (n = 39), with most events being mild to moderate in severity.
Treatment-emergent adverse events that were reported in 55% of patients were nasopharyngitis (reported in 
Discussion
In daily clinical practice, it is very important to explain the concepts of onset of action and plateau of efficacy to patients at the initiation of therapy. Recently the first randomized, double-blind, placebo-controlled study of etanercept in patients with severe advanced AS demonstrated that etanercept has significant activity in this patient population [14] . In the 12-week open-label extension of this study reported here, we have shown that continuing etanercept treatment provides further beneficial improvements in the signs and symptoms of AS in patients with severe and advanced disease.
Patients experienced further improvements in composite index scores during the 12-week open-label extension, with no plateauing effect observed over the 24 weeks of treatment. With longer-term etanercept therapy, the proportion of patients achieving BASDAI 50, ASAS 20 and ASAS 40 responses or ASAS partial remission continued to increase. The proportion of patients with clinically significant or major improvements in ASDAS-CRP, as well as the proportion of patients achieving ASDAS-CRP inactive disease status, similarly increased during the open-label extension period. Improvements in the signs and symptoms of disease were also observed in patients who The continued improvement in patients receiving etanercept for a second 12-week treatment period could be explained by the study design. Thus in the first 12-week treatment period patients were blinded to treatment and were not subsequently told whether they received placebo or etanercept; however, all patients in the second half of the study knew they were on active drug, perhaps affecting their perception of treatment benefits. The second possibility is that the results reflect a real biological effect such that a plateau was not reached for this stringent outcome measure during the first 12-week treatment period. However, it should be noted that in the seven patients who achieved a BASDAI 50% improvement only at week 24, a relevant improvement was observed after 12 weeks (median change from baseline in BASDAI of 35.9%). These data are not in contradiction to the ASAS recommendations for the use of anti-TNF agents in patients with AS [21] . Thus the ASAS group recommends an assessment of treatment success or failure after a trial period of 512 weeks based on a BASDAI 50% improvement or absolute change of 2 [21] . Our data suggest that in the case of a relevant improvement in BASDAI score at week 12 (i.e. >30%), an extension of the trial period should be considered.
Most disability (spinal mobility restriction and impairment of physical function) is correlated with radiographic structural damage [22] , yet 24 weeks' etanercept treatment resulted in improved overall spinal mobility and functioning. Additionally, 24 weeks' etanercept treatment reduced total back pain and improved disease activity to a greater degree than 12 weeks' treatment in the placebo/etanercept group.
On the other hand, while patient-reported outcomes such as BASDAI and functioning continuously improved during the open-label study period, the objectively measured CRP levels rapidly decreased following initiation of etanercept, reaching a plateau 2 weeks after the initiation of treatment. Thus it appears that while the anti-inflammatory effects of etanercept reach their maximal levels relatively quickly, the effects of etanercept on function and pain (as reported by the patient) are more gradual and develop with continued treatment following the initial reduction in inflammation.
The magnitude of effect in this study, in terms of change of disease status obtained with 24 weeks of etanercept therapy in active, severe and advanced AS, is consistent with that previously reported in a similar 24-week randomized, double-blind study that compared the efficacy and tolerability of etanercept and placebo in patients with less advanced, moderate-to-severe active AS [7] .
Although this study was not specifically designed to assess safety, results showed that 24 weeks' etanercept therapy was associated with few adverse events, most of which were mild to moderate in severity. This is consistent with a previous 24-week study [7] and two other long-term studies ($24 years) [23, 24] that investigated the longerterm tolerability of etanercept in patients with AS. Furthermore, relatively similar incidences of adverse events were reported with longer-term etanercept to that observed in short-term studies [6, 10] .
One of the difficulties in this trial was ensuring that the inclusion criteria would clearly represent a patient population with severe and advanced AS. As discussed in our publication of the randomized, double-blind, placebocontrolled study results we believe that a strength of our study was that a clearly defined patient population was established and adhered to [14] .
Limitations of this open-label extension include the small sample size and the fact that a longer extension period (of >1 year) would have been ideal. With the rapid onset of action and the sustainability of the response observed with etanercept in patients with AS, it was believed that a 24-week trial with a small sample of patients with advanced disease was appropriate to look for a possible plateauing effect in this advanced and severe patient population. This is the first randomized study to specifically evaluate the longer-term efficacy of etanercept in patients with severe and advanced AS, which is characterized by radiographic spinal damage and inflammation. Results showed that continued etanercept therapy was beneficial in terms of improving signs and symptoms of disease, thereby emphasizing the importance of treatment in patients with advanced, active AS. This study highlights that in addition to the rapid onset of efficacy, the beneficial effects of etanercept in patients with severe and advanced disease increase with time: there is a high probability of a clinically relevant effect within 2 weeks and further improvement continues when treatment is administered for up to 24 weeks.
Rheumatology key messages
. Etanercept is effective in AS even at an advanced stage. . The clinical relevance of etanercept therapy in advanced AS is observed within 2 weeks. . Symptoms of advanced AS continue to improve after up to 24 weeks' etanercept therapy.
